HC Wainwright Has Bullish Forecast for MIST Q1 Earnings

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Research analysts at HC Wainwright upped their Q1 2025 earnings per share estimates for Milestone Pharmaceuticals in a research note issued on Tuesday, April 1st. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.11) per share for the quarter, up from their prior estimate of ($0.18). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ Q1 2025 earnings at ($0.11) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.44) EPS, Q1 2026 earnings at ($0.23) EPS, Q1 2026 earnings at ($0.23) EPS, Q2 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.85) EPS, FY2026 earnings at ($0.85) EPS, FY2027 earnings at ($0.63) EPS, FY2027 earnings at ($0.63) EPS, FY2028 earnings at ($0.30) EPS, FY2028 earnings at ($0.30) EPS, FY2029 earnings at $0.28 EPS and FY2029 earnings at $0.28 EPS.

Several other research analysts also recently issued reports on the stock. TD Cowen downgraded shares of Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, April 1st. TD Securities downgraded Milestone Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 1st.

Milestone Pharmaceuticals Stock Performance

Shares of MIST stock opened at $0.70 on Friday. The company has a market capitalization of $37.12 million, a price-to-earnings ratio of -0.86 and a beta of 1.38. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40. Milestone Pharmaceuticals has a one year low of $0.67 and a one year high of $2.75. The company’s 50-day moving average is $1.87 and its 200 day moving average is $1.81.

Institutional Trading of Milestone Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Jones Financial Companies Lllp lifted its position in Milestone Pharmaceuticals by 1,000.0% during the fourth quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock valued at $26,000 after purchasing an additional 10,000 shares during the period. National Bank of Canada FI lifted its holdings in shares of Milestone Pharmaceuticals by 163.4% during the 4th quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock valued at $44,000 after buying an additional 11,600 shares during the period. PVG Asset Management Corp purchased a new position in shares of Milestone Pharmaceuticals in the 3rd quarter worth $46,000. Cubist Systematic Strategies LLC bought a new stake in shares of Milestone Pharmaceuticals in the fourth quarter worth $73,000. Finally, XTX Topco Ltd purchased a new stake in Milestone Pharmaceuticals during the fourth quarter valued at $80,000. 86.18% of the stock is currently owned by institutional investors.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.